

1 **TITLE**

2 Mechano-arrhythmogenicity is enhanced during late repolarisation in ischemia and driven by a

3 TRPA1-, calcium-, and reactive oxygen species-dependent mechanism

4 **AUTHORS**

5 Breanne A Cameron, BSc<sup>1</sup>

6 T Alexander Quinn, PhD<sup>1,2\*</sup>

7 **AFFILIATIONS**

8 <sup>1</sup>Department of Physiology and Biophysics, Dalhousie University, Halifax, Canada

9 <sup>2</sup>School of Biomedical Engineering, Dalhousie University, Halifax, Canada

10 **SHORT TITLE**

11 Mechanisms of ischemic mechano-arrhythmogenicity

12 **\*CORRESPONDENCE**

13 T Alexander Quinn, PhD

14 Department of Physiology and Biophysics

15 Dalhousie University

16 5850 College St, Lab 4J

17 Halifax, NS B3H 4R2

18 Phone: +1 902 494 4349

19 Email: [alex.quinn@dal.ca](mailto:alex.quinn@dal.ca)

20 **CONFLICTS OF INTEREST:** None.

21

22 **ABSTRACT**

23 **Background:** Cardiac dyskinesia in regional ischemia results in arrhythmias through  
24 mechanically-induced changes in electrophysiology ('mechano-arrhythmogenicity') that involve  
25 ischemic alterations in voltage-calcium ( $\text{Ca}^{2+}$ ) dynamics, creating a vulnerable period (VP) in late  
26 repolarisation. **Objective:** To determine cellular mechanisms of mechano-arrhythmogenicity in  
27 ischemia and define the importance of the VP. **Methods and Results:** Voltage- $\text{Ca}^{2+}$  dynamics  
28 were simultaneously monitored in rabbit ventricular myocytes by dual-fluorescence imaging to  
29 assess the VP in control and simulated ischemia (SI). The VP was longer in SI than in control  
30 ( $146 \pm 7$  vs  $54 \pm 8$ ms;  $p < 0.0001$ ) and was reduced by blocking  $\text{K}_{\text{ATP}}$  channels with glibenclamide  
31 ( $109 \pm 6$ ms;  $p < 0.0001$ ). Cells were rapidly stretched (10-18% increase in sarcomere length over  
32 110-170ms) with carbon fibres during diastole or the VP. Mechano-arrhythmogenicity, associated  
33 with stretch and release in the VP, was greater in SI than control (7 vs 1% of stretches induced  
34 arrhythmias;  $p < 0.005$ ) but was similar in diastole. Arrhythmias during the VP were more complex  
35 than in diastole (100 vs 69% had sustained activity;  $p < 0.05$ ). In the VP, incidence was reduced  
36 with glibenclamide (2%;  $p < 0.05$ ), by chelating intracellular  $\text{Ca}^{2+}$  (BAPTA; 2%;  $p < 0.05$ ), blocking  
37 mechano-sensitive TRPA1 (HC-030031; 1%;  $p < 0.005$ ), or by scavenging (NAC; 1%;  $p < 0.005$ ) or  
38 blocking reactive oxygen species (ROS) production (DPI; 2%;  $p < 0.05$ ). Ratiometric  $\text{Ca}^{2+}$  imaging  
39 revealed that SI increased diastolic  $\text{Ca}^{2+}$  ( $+9 \pm 1\%$ ,  $p < 0.0001$ ), which was not prevented by HC-  
40 030031 or NAC. **Conclusion:** In ischemia, mechano-arrhythmogenicity is enhanced specifically  
41 during the VP and is mediated by ROS, TRPA1, and  $\text{Ca}^{2+}$ .

42 **KEYWORDS**

43 Arrhythmias; stretch; mechano-electric coupling; ischemia; calcium

44

## 45 INTRODUCTION

46 Regional ischemia due to coronary artery occlusion is associated with deadly ventricular  
47 arrhythmias.<sup>1</sup> Mechanical heterogeneity, acting through mechano-electric coupling mechanisms  
48 ('mechano-arrhythmogenicity'), is thought to contribute to this arrhythmogenesis,<sup>2</sup> and is  
49 supported by the strong correlation between regional ventricular wall motion abnormalities and  
50 arrhythmias in patients with coronary artery disease.<sup>3</sup> In animal models, these arrhythmias have  
51 been shown to originate at the ischemic border,<sup>4</sup> a site of systolic stretch of weakened ischemic  
52 myocardium.<sup>5</sup> Consequently, arrhythmia incidence in ischemia is ventricular load-dependent,<sup>4</sup>  
53 with distension of the ischemic region being a strong predictor of ventricular fibrillation.<sup>6,7</sup>  
54 Computational modelling suggests that mechano-arrhythmogenicity in ischemia is the result of  
55 stretch-activated ion channel-mediated depolarisation at the ischemic border, which contributes  
56 to ectopic foci (if supra-threshold) or conduction slowing and block (if sub-threshold).<sup>8</sup> Yet, the  
57 molecular identity of the mechano-sensitive ion channels involved remains unknown.<sup>9</sup>

58 Recent evidence from rabbit isolated heart studies suggests that ventricular mechano-  
59 arrhythmogenicity in regional ischemia is Ca<sup>2+</sup>-mediated,<sup>10</sup> and may relate to a VP in late  
60 repolarisation during which a temporal dissociation between the recovery of membrane potential  
61 and cytosolic Ca<sup>2+</sup> results in Ca<sup>2+</sup> remaining elevated as myocytes become re-excitabile.<sup>10,11</sup>  
62 Further work showed that the mechano-sensitive,<sup>12</sup> Ca<sup>2+</sup>-permeable<sup>13</sup> transient receptor potential  
63 ankyrin 1 (TRPA1) channel<sup>14</sup> can act as a source for Ca<sup>2+</sup>-mediated mechano-arrhythmogenicity  
64 in ventricular myocytes by triggering premature excitation and creating a substrate for more  
65 complex arrhythmic activity.<sup>15</sup> Since the response of TRPA1 to mechanical stimulation is  
66 dependent on its baseline activity,<sup>16</sup> which is increased in ischemia<sup>17</sup> as it is agonised by multiple

67 ischemic factors (*e.g.*, increased cytosolic  $\text{Ca}^{2+}$  and ROS),<sup>18,19</sup> TRPA1 may be involved in  
68 ischemic mechano-arrhythmogenicity.

69 Other mechano-sensitive processes may additionally contribute to arrhythmogenesis in  
70 ischemia. Stretch is known to increase NADPH oxidase-dependent ROS production (X-ROS)<sup>20</sup>  
71 and subsequent sarcoplasmic  $\text{Ca}^{2+}$  release events *via* ryanodine receptors (RyR).<sup>21</sup> As these  
72 mechanically-induced effects are enhanced in ischemia,<sup>22</sup> regional stretch may lead to localised  
73 increases in ROS and cytosolic  $\text{Ca}^{2+}$ , resulting in arrhythmic activity.<sup>23</sup>

74 The goal of this study was to investigate cellular mechanisms of ischemic mechano-  
75 arrhythmogenicity and the importance of the VP. Rabbit isolated ventricular myocytes exposed  
76 to simulated ischemic (SI) conditions were stretched in diastole and during the VP using a  
77 carbon-fibre-based system, combined with dual-parametric fluorescence imaging of voltage and  
78 cytosolic  $\text{Ca}^{2+}$ , video-based measurement of sarcomere dynamics, and pharmacological  
79 interrogations. It was hypothesised that the incidence of stretch-induced arrhythmias would be  
80 greatest in the VP, and driven by a TRPA1-,  $\text{Ca}^{2+}$ -, and ROS-mediated mechanism.

81

## 82 **METHODS**

83 **Ethics.** Experiments were conducted in accordance with the ethical guidelines of the Canadian  
84 Council on Animal Care with all protocols approved by the Dalhousie University Committee for  
85 Laboratory Animals. Details have been described following the Minimum Information about a  
86 Cardiac Electrophysiology Experiment (MICEE) reporting standard.<sup>24</sup>

87

88 **Ventricular myocyte isolation.** Rabbit ventricular myocytes were enzymatically isolated as  
89 previously described.<sup>15</sup> Details are available in the supplemental methods.

90 **Carbon fibre-based cell stretch.** Cells were subjected to axial stretch using the carbon fibre (CF)  
91 method previously described for stretch of ventricular myocytes.<sup>15,21</sup> Figure 2 shows a schematic  
92 for the stretch protocol. Contractile function and characteristics of stretch were assessed by  
93 monitoring sarcomere length and piezo-electric translators (PZT) and CF tip positions to determine  
94 incidence and classification of mechano-arrhythmogenicity (Fig. 2). Details can be found in the  
95 supplement.

96  
97 **Pharmacology.** Pharmacologic agents were dissolved in distilled water or dimethyl sulfoxide  
98 (DMSO) as appropriate. Agents included: BAPTA-AM (1  $\mu$ M, 20 min pre-incubation; Abcam),  
99 dantrolene (1  $\mu$ M, 5 min pre-incubation; Abcam), HC-030031 (10  $\mu$ M, 30 min pre-incubation;  
100 Abcam), N-acetyl-L-cysteine (NAC; 10 mM, 20 min pre-incubation; Sigma),  
101 diphenyleiiodonium (DPI; 3  $\mu$ M, 60 min pre-incubation; Abcam), or glibenclamide (20  $\mu$ M, 15  
102 min pre-incubation; Abcam).

103  
104 **Fluorescence imaging.** Figure 1 shows a schematic of the single-excitation/dual-emission  
105 fluorescence imaging technique to monitor voltage-Ca<sup>2+</sup> dynamics in isolated ventricular  
106 myocytes, adapted from our previous work<sup>15</sup>. Ratiometric Ca<sup>2+</sup> levels were assessed using Fura  
107 Red-AM (5  $\mu$ M; AAT Bioquest). Detailed methodology is included in the supplement.

108  
109 **Statistics.** Statistics were performed using GraphPad Prism 9. Differences in arrhythmia incidence  
110 were assessed using chi-square contingency tables and Fisher's exact test. Differences were  
111 assessed by two-tailed, paired or unpaired Student's t-test (for normally distributed data) or  
112 Wilcoxon matched-pairs test (for data that was not normally distributed), one-way ANOVA with

113 Tukey *post-hoc* tests (for normally distributed data), or Kruskal-Wallis with Dunn's multiple  
114 comparisons test (for non-normally distributed data), where appropriate. A *p*-value of  $< 0.05$  was  
115 considered significant. The relevant test and number of replicates is indicated in each figure  
116 caption ( $N$  = rabbits,  $n$  = cells,  $m$  = stretches,  $c$  = complex arrhythmias).

117

## 118 **RESULTS**

119 **Simulated ischemia creates a VP that can be reduced by blocking  $K_{ATP}$  channels.** The  
120 fluorescence imaging approach for APD and CaTD (Fig. 1a) revealed that exposure to SI (5  
121 minutes) decreased both APD ( $APD_{50,NT} = 381 \pm 11$  ms *vs*  $APD_{50,SI} = 221 \pm 8$  ms;  $p < 0.0001$ ) and  
122 CaTD ( $CaTD_{80,NT} = 433 \pm 9$  ms *vs*  $CaTD_{80,SI} = 358 \pm 8$  ms;  $p < 0.0001$ ) compared to control (Fig. 1b,  
123 c and Supplemental Fig. 1a, b). This increased the VP ( $= (CaTD_{80} - APD_{50}) + ECC$ ) in ischemic  
124 cells ( $VP_{NT} = 66 \pm 12$  ms *vs*  $VP_{SI} = 145 \pm 6$  ms;  $p < 0.0001$ ; Fig. 1d). The SI-induced decrease in APD  
125 was attenuated by pre-incubation with the  $K_{ATP}$  antagonist glibenclamide ( $APD_{50,GLIB} = 282 \pm 8$  ms;  
126  $p < 0.0001$ ; Fig. 1b, c, Supplemental Fig. 1c), with no effect on CaTD ( $CaTD_{80,GLIB} = 384 \pm 8$  ms),  
127 ultimately reducing the VP ( $VP_{GLIB} = 109 \pm 6$  ms;  $p < 0.05$ ; Fig. 1d).

128

129 **Transient stretch of ventricular myocytes results in premature contractions and complex**  
130 **arrhythmias.** Stretch of ventricular myocytes with CFs (Fig. 2a, b) resulted in premature  
131 contractions (1-2 unstimulated contractions; Fig. 2d) and complex activity, including delayed  
132 transient rhythm disturbances (Fig. 2e) and sustained arrhythmic activity that either spontaneously  
133 resolved (Fig. 2f), or that was terminated by an additional stretch (Fig. 2g). To ensure arrhythmic  
134 activity was not the result of stretch-induced cellular damage, contractile function was measured  
135 before and after completion of a stretch-induced event, which showed no change, suggesting that

136 cells were not damaged (Supplemental Fig. 2). Stretch characteristics were measured at increasing  
137 PZT displacements, corresponding with an increase in percent sarcomere stretch ( $10.7\pm 1$ ,  $16\pm 2$ ,  
138 and  $18.5\pm 2\%$ ;  $p<0.005$ ), stretched sarcomere length ( $2.04\pm 0.02$ ,  $2.15\pm 0.02$ , and  $2.21\pm 0.03$   $\mu\text{m}$ ;  
139  $p<0.0001$ ), and stretch force ( $0.55\pm 0.01$ ,  $0.80\pm 0.05$ , and  $0.98\pm 0.05$   $\mu\text{N}$ ;  $p<0.0001$ ). Importantly,  
140 while stretch characteristics scaled with PZT displacement similarly in all cells, absolute values of  
141 stretch parameters varied between cells, reflecting physiological ventricular heterogeneity in  
142 intrinsic cell stiffness and response to an ischemic insult.<sup>25</sup> Notably, the diastolic sarcomere length  
143 within a given cell was maintained after stretch at each PZT displacement, indicating that CF  
144 slippage and subsequent cell buckling did not occur (Supplemental Fig. 3). Surprisingly, increased  
145 PZT displacement did not correspond with an increase in arrhythmias (though a clear trend was  
146 present, Supplemental Fig. 4).

147

148 **Mechano-arrhythmogenicity is enhanced in late repolarisation in ischemic cells.** To determine  
149 whether mechano-arrhythmogenicity is dependent on stretch timing, stretch was applied in mid-  
150 diastole or during the VP in control and ischemic cells. We showed that the incidence of mechano-  
151 arrhythmogenicity was increased in ischemic cells compared to control in the VP (6.8 vs 1.2% of  
152 stretches induced arrhythmias;  $p<0.005$ ) but not in diastole. Additionally, in ischemic cells,  
153 arrhythmias in the VP were proportionally more complex than those generated in diastole (100 vs  
154 69% of events had complex activity;  $p<0.05$ ; Fig. 3). Fluorescence-based measurement of APD  
155 and CaTD during stretch was performed in a subset of cells to assess the temporal relation of the  
156 stretch pulse to the VP, and its effect on arrhythmia incidence. This showed that 96% of cases had  
157 either stretch, stretch-release, or both occur within the cell-specific VP, with 4% of stretches  
158 missing it entirely (Supplemental Fig. 5a). Of those cases with some portion of the stretch pulse

159 within the VP, 52% had both stretch and release within the VP, 41% only had release, and 7% of  
160 cells only stretch occurred in the VP (Supplemental Fig. 5b). Yet, 100% of cases that resulted in a  
161 mechanically-induced arrhythmia were attributed to both stretch and release within the VP (which  
162 represented 50% of those stretches; Supplemental Fig. 5b, c). We then sought to determine whether  
163 mechano-arrhythmogenicity in ischemic cells was affected by reduced VP duration by blocking  
164  $K_{ATP}$  channels (Fig. 1b, d). Pre-incubating ischemic cells with glibenclamide reduced arrhythmia  
165 incidence in the VP compared to ischemia alone (2.1 vs 6.8% of stretches;  $p < 0.05$ ) with no effect  
166 on diastolic incidence (Fig. 3).

167

168 **TRPA1 channels and ROS mediate ischemic mechano-arrhythmogenicity during the VP.** We  
169 next sought to determine mechanisms underlying the observed increase in mechano-  
170 arrhythmogenicity during the ischemic VP. As we previously showed that TRPA1 channels can  
171 act as a source for mechano-arrhythmogenicity,<sup>15</sup> and as it is known that TRPA1 channel activity  
172 is increased in ischemia,<sup>17</sup> we tested the effects of a specific TRPA1 blocker on arrhythmia  
173 incidence. Pre-incubating ischemic cells with HC-030031 reduced arrhythmia incidence in the VP  
174 (0.9 vs 6.8%;  $p < 0.005$ ), with no change in diastolic incidence (Fig. 4a), suggesting a role for  
175 TRPA1 channels in ischemic mechano-arrhythmogenicity.

176 Interestingly, while fluorescence imaging our ischemic cells, we observed a potentiated  
177 mechano-arrhythmogenicity during the VP (28.6 vs 6.8%;  $p < 0.005$ ), as well as an increase in  
178 diastole (14.3 vs 4.9%;  $p < 0.05$ ; Fig. 4b). However, this increase was only greater when the cells  
179 were exposed to photo-activation of the fluorescent dyes (Fig. 4b). As fluorophore photo-  
180 activation is associated with the generation of ROS,<sup>26</sup> which is increased in ischemia,<sup>22</sup> ROS might  
181 also play a role in mechano-arrhythmogenicity in ischemic cells. To test this, we pre-incubated



182 ischemic cells with NAC to chelate intracellular ROS and found that arrhythmia incidence in the  
183 VP decreased compared to ischemia alone (0.8 vs 6.8%;  $p < 0.0005$ ), with no effect in diastole (Fig.  
184 4c). Further, as we have shown that X-ROS production is enhanced in ischemia,<sup>22</sup> we tested the  
185 effect of the NOX2 inhibitor DPI to block X-ROS production in ischemic cells. DPI also reduced  
186 arrhythmia incidence in the VP (2.4 vs 6.8%;  $p < 0.05$ ) with no diastolic effect (Fig. 4c). Combined,  
187 these data suggest that ROS, possibly through its effects on TRPA1,<sup>19</sup> is a mediator of ischemic  
188 mechano-arrhythmogenicity.

189

190 **Cytosolic Ca<sup>2+</sup> loading in ischemia is necessary, but not sufficient for enhanced mechano-**  
191 **arrhythmogenicity during the VP.** As we have previously shown that increased cytosolic Ca<sup>2+</sup>  
192 is necessary for TRPA1-mediated mechano-arrhythmogenicity in rabbit ventricular myocytes,<sup>15</sup>  
193 we sought to assess whether it mediates the observed stretch-induced arrhythmias. We first  
194 buffered cytosolic Ca<sup>2+</sup> in ischemic cells with BAPTA-AM and found that arrhythmia incidence  
195 was decreased in the VP (2.4 vs 6.8%;  $p < 0.05$ ; Fig. 5a). While this supports a necessary role for  
196 Ca<sup>2+</sup> in ischemic mechano-arrhythmogenicity, surprisingly, arrhythmia incidence in these cells  
197 was simultaneously increased with stretch in diastole compared to control (8.5 vs 3.1%;  $p < 0.05$ ;  
198 Fig. 5a). Next, we assessed whether Ca<sup>2+</sup> release *via* RyR may be involved in the observed  
199 arrhythmogenic role of cytosolic Ca<sup>2+</sup> (like X-ROS, stretch-induced Ca<sup>2+</sup>-sparks are also  
200 enhanced by ischemia).<sup>22</sup> To test this, RyR in ischemic cells were stabilised in their closed state  
201 with dantrolene, however, this had no effect on arrhythmia incidence with stretch in diastole or  
202 the VP (Fig. 5a). Finally, as Ca<sup>2+</sup> loading in ischemia itself can be arrhythmogenic,<sup>27</sup> we wanted  
203 to assess changes in cytosolic Ca<sup>2+</sup> levels in our model. Through ratiometric Ca<sup>2+</sup> imaging (using  
204 Fura Red-AM), we found that diastolic Ca<sup>2+</sup> was increased with ischemia exposure (+9.3±1.1%

205 change  $p < 0.0001$ ). Yet, while block of TRPA1 (with HC-030031) or chelation of ROS (with  
206 NAC) decreased mechano-arrhythmogenicity in ischemia, they did not prevent the increase in  
207 cytosolic  $\text{Ca}^{2+}$  ( $+10.0 \pm 1.0$  or  $+12.3 \pm 1.4\%$ ), suggesting that neither TRPA1 nor ROS are solely  
208 responsible for the elevated  $\text{Ca}^{2+}$  levels in our ischemic cells (Fig. 5b).

209

## 210 **DISCUSSION**

211 In this study, we aimed to define cellular mechanisms of mechano-arrhythmogenicity and the  
212 importance of the VP in ischemia using rabbit ventricular myocytes exposed to SI and subjected  
213 to controlled stretch. We showed that mechano-arrhythmogenicity was enhanced only in the VP  
214 during SI, that arrhythmias generated in the VP were more complex than those in diastole, and  
215 that arrhythmogenesis involved TRPA1, cytosolic  $\text{Ca}^{2+}$ , and ROS.

216

217 **Role of the VP in  $\text{Ca}^{2+}$ -mediated mechano-arrhythmogenicity during ischemia.** In the whole  
218 heart, ischemia-induced  $\text{K}_{\text{ATP}}$  activation causes a larger decrease in APD than CaTD, resulting in  
219 a VP for  $\text{Ca}^{2+}$ -mediated arrhythmic activity.<sup>11,27</sup> Elevated cytosolic  $\text{Ca}^{2+}$  can be arrhythmogenic by  
220 driving forward-mode sodium/ $\text{Ca}^{2+}$ -exchanger (NCX) activity, approaching the threshold for  
221 premature excitation.<sup>28</sup> Indeed, it has been shown that the generation of a VP through  
222 pharmacological  $\text{K}_{\text{ATP}}$  activation<sup>11,15</sup> facilitates arrhythmogenesis. In ischemia, arrhythmogenicity  
223 of the VP may be exacerbated by transmural heterogeneity of  $\text{K}_{\text{ATP}}$  channel expression.<sup>29</sup> Acute  
224 stretch may further increase cytosolic  $\text{Ca}^{2+}$  *via*  $\text{Ca}^{2+}$  influx through mechano-sensitive channels,<sup>30</sup>  
225 which may also drive depolarisation and premature excitation by sodium influx.<sup>9</sup> Furthermore,  
226 stretch has been shown to increase the affinity of myofilaments for  $\text{Ca}^{2+}$ , such that systolic stretch  
227 causes excess myofilament  $\text{Ca}^{2+}$  loading.<sup>30</sup> Upon release, dissociation of myofilament-bound  $\text{Ca}^{2+}$

228 can produce a surge in cytosolic  $\text{Ca}^{2+}$ , which may induce SR  $\text{Ca}^{2+}$  release and generate  $\text{Ca}^{2+}$  waves,  
229 or drive NCX-mediated membrane depolarisation.<sup>31</sup> Combined, these mechanisms may be  
230 sufficient to drive mechano-arrhythmogenicity in the VP.

231 In this study, we demonstrated the emergence of a VP in cells exposed to SI (Fig. 1). When  
232 transient stretch was timed to the VP, there was an increase in arrhythmia incidence that did not  
233 occur with stretch in diastole (Figure 3), revealing a temporal-dependence of ischemic mechano-  
234 arrhythmogenicity. Reducing the VP by blocking  $\text{K}_{\text{ATP}}$  channels (Fig. 1) resulted in an associated  
235 reduction in arrhythmia incidence (Fig. 3), further supporting the role of the VP. The idea of whether  
236 stretch, stretch-release, or both, is critical to mechano-arrhythmogenicity remains an open  
237 question. However, our fluorescence measurements of APD, CaTD, and the VP during stretch  
238 revealed that all stretches that resulted in an arrhythmia stretched and released within the VP  
239 (Supplemental Fig. 5), suggesting that this combination may be necessary for mechano-  
240 arrhythmogenicity. This could partly explain why we did not see a higher incidence of arrhythmias  
241 in ischemic cells, as well as why reducing (but not eliminating) the VP attenuated arrhythmia  
242 incidence.

243

244 **Role of mechano-sensitive TRPA1 channels in ischemic mechano-arrhythmogenicity.** A  
245 principal question underlying mechano-arrhythmogenicity is the identity of the mechano-sensitive  
246 ion channels involved.<sup>9</sup> We demonstrated that TRPA1 channels can act as a source for  $\text{Ca}^{2+}$ -  
247 mediated mechano-arrhythmogenicity.<sup>15</sup> The potential role for TRPA1 channels in stretch-induced  
248 arrhythmias during ischemia is supported by their inherent mechano-sensitivity,<sup>12</sup> preferential  
249 permeability to  $\text{Ca}^{2+}$ ,<sup>13</sup> and their activation by ischemic factors, namely ROS<sup>19</sup> and  $\text{Ca}^{2+}$ .<sup>18</sup> (which  
250 is bimodal, such that increased cytosolic  $\text{Ca}^{2+}$  enhances inward current to a point, after which

251 greater increases in  $\text{Ca}^{2+}$  begin to inactivate channels).<sup>32</sup> To test for their involvement in our cells,  
252 the specific TRPA1 blocker HC-030031 was used, which reduced arrhythmia incidence  
253 specifically in the VP (Fig. 4), supporting the role of TRPA1 channels in ischemic mechano-  
254 arrhythmogenicity.

255 The finding that mechano-arrhythmogenicity was exclusively increased during late repolarisation  
256 may also be related to a specific property of TRPA1 channels. While TRPA1 has been classically  
257 considered a non-voltage dependent channel, it has recently been shown that, under normal  
258 conditions, it is activated and inactivated by voltage at potentials outside the physiological range  
259 (+90 to +170 mV) so that voltage is not a relevant factor for its kinetics.<sup>33</sup> However, when exposed  
260 to non-electrophilic agonists<sup>34</sup> or elevated  $\text{Ca}^{2+}$ ,<sup>18</sup> there is a leftward shift in its voltage activation  
261 into the physiological range. Further, continual TRPA1 agonism has been shown to de-sensitise  
262 the channel to  $\text{Ca}^{2+}$ -mediated inhibition, effectively resulting in a sensitised channel with a  
263 physiological voltage dependence.<sup>34</sup> Thus, in ischemia, increases in cytosolic  $\text{Ca}^{2+}$  and ROS may  
264 not only increase TRPA1 channel activity directly, but also indirectly through reduced  $\text{Ca}^{2+}$ -  
265 mediated inhibition and modulation of its voltage dependence.

266

267 **Role of intracellular ROS in ischemic mechano-arrhythmogenicity.** ROS production is  
268 increased in ischemia,<sup>22</sup> which may contribute to mechano-arrhythmogenicity by increasing  
269 TRPA1 activity,<sup>19</sup> and thus its response to mechanical stimulation.<sup>16</sup> The potential mechanistic  
270 role of ROS in our ischemic cells was first revealed in our fluorescence imaging experiments, as  
271 fluorophore photo-activation, which generates ROS,<sup>26</sup> resulted in an overall increase in arrhythmia  
272 incidence (Fig. 4b). To more directly investigate the contribution of ROS to ischemic mechano-  
273 arrhythmogenicity, intracellular ROS was scavenged with NAC, or its NOX2 production was

274 blocked with DPI, both of which resulted in a decrease in arrhythmia incidence in the VP (Fig. 4c).  
275 The importance of ROS for mechano-arrhythmogenicity may extend beyond its potential effect on  
276 TRPA1 activity. X-ROS has also been shown to modulate RyR Ca<sup>2+</sup> release,<sup>22</sup> so it may  
277 additionally contribute to mechano-arrhythmogenicity through effects on cytosolic Ca<sup>2+</sup>.

278

279 **Role of cytosolic Ca<sup>2+</sup> in ischemic mechano-arrhythmogenicity.** Ischemic mechano-  
280 arrhythmogenicity in the VP appears to be mediated by cytosolic Ca<sup>2+</sup>, which is increased in  
281 ischemia.<sup>27</sup> This was supported by the observation that chelating cytosolic Ca<sup>2+</sup> with BAPTA  
282 reduced arrhythmia incidence in the VP (although, paradoxically it increased premature  
283 contractions in diastole, perhaps due to an increase in the driving force for Ca<sup>2+</sup> influx with  
284 cytosolic Ca<sup>2+</sup> buffering; Fig. 5a) This suggests that not only is Ca<sup>2+</sup> involved in stretch-induced  
285 arrhythmias during ischemia, but also their stretch-timing dependence. Ischemic potentiation of  
286 stretch-induced RyR release has been suggested to be arrhythmogenic by contributing to cytosolic  
287 Ca<sup>2+</sup> load and NCX-mediated membrane depolarisation.<sup>22</sup> However, dantrolene (a RyR stabiliser)  
288 had no effect on arrhythmia incidence, suggesting that mechano-sensitive RyR release was not  
289 playing a critical role in arrhythmogenesis. Another potential mechanism of increased cytosolic  
290 Ca<sup>2+</sup> is its direct activation of TRPA1 channels.<sup>18</sup> Importantly, as cytosolic Ca<sup>2+</sup> was not reduced  
291 by HC-030031 or NAC (Fig. 5b), despite a reduction in the incidence of stretch-induced arrhythmias  
292 (Figs. 4a, b), it appears that cytosolic Ca<sup>2+</sup> is necessary, but not sufficient for ischemic mechano-  
293 arrhythmogenicity.

294

295 **CONCLUSION**

296 Ultimately, the observed ischemic mechano-arrhythmogenicity within the VP appears to relate to  
297 an increase in TRPA1 channel activity, driven by elevated intracellular ROS and cytosolic Ca<sup>2+</sup>  
298 levels. Targeting TRPA1 channels in SI may help prevent electrical dysfunction and myocardial  
299 damage.<sup>17</sup> The same may be true in other pathologies associated with changes in cardiac mechanics  
300 and TRPA1 modulating factors,<sup>33</sup> such as ventricular pressure overload, in which TRPA1 has been  
301 shown to be involved in pathological changes<sup>35</sup> and mechano-arrhythmogenicity is thought to  
302 occur,<sup>5</sup> making TRPA1 channels a novel anti-arrhythmic target with exciting therapeutic potential.

303

304 **STATEMENTS**

305 **Acknowledgements.** Carbon fibres were a gift from Jean-Yves LeGuennec. We thank G. Iribe  
306 and K. Kaihara for technical assistance with cell stretch and the ischemic model design and I.  
307 Uzelac for assistance with electronic LED control.

308 **Sources of funding.** This work was supported by the Dalhousie Medical Research Foundation  
309 (Hoegg Graduate Studentship to B.A.C and Capital Equipment Grant to T.A.Q.), the Canadian  
310 Institutes of Health Research (MOP 342562 to T.A.Q.), the Natural Sciences and Engineering  
311 Research Council of Canada (RGPIN-2016-04879 to T.A.Q.), the Heart and Stroke Foundation of  
312 Canada (National New Investigator Award to T.A.Q.), and the Canadian Foundation for  
313 Innovation (32962 to T.A.Q.).

314 **Author contributions.** B.A.C. and T.A.Q. designed the study, interpreted the data, and wrote the  
315 manuscript; B.A.C. performed the experiments and analysed the data. All authors read and  
316 approved the manuscript.

317 **REFERENCES**

- 318 1. Rubart M, Zipes DP. Mechanisms of sudden cardiac death. *J Clin Invest* 2005;115:2305–  
319 2315. doi:10.1172/jci26381.
- 320 2. Quinn TA, Kohl P. Cardiac mechano-electric coupling: acute effects of mechanical  
321 stimulation on heart rate and rhythm. *Physiol Rev* 2021;101:37–92.  
322 doi:10.1152/physrev.00036.2019.
- 323 3. Siogas K, Pappas S, Graekas G, Goudevenos J, Liapi G, Sideris DA. Segmental wall motion  
324 abnormalities alter vulnerability to ventricular ectopic beats associated with acute increases  
325 in aortic pressure in patients with underlying coronary artery disease. *Heart* 1998;79:268.  
326 doi:10.1136/hrt.79.3.268.
- 327 4. Coronel R, Wilms-Schopman FJG, deGroot JR. Origin of ischemia-induced phase 1b  
328 ventricular arrhythmias in pig hearts. *J Am Coll Cardiol* 2002;39:166–176.  
329 doi:10.1016/s0735-1097(01)01686-2.
- 330 5. Quinn TA. The importance of non-uniformities in mechano-electric coupling for ventricular  
331 arrhythmias. *J Interv Card Electr* 2014;39:25–35. doi:10.1007/s10840-013-9852-0.
- 332 6. Barrabés JA, Inserte J, Rodríguez-Sinovas A, Ruiz-Meana M, Garcia-Dorado D. Early  
333 regional wall distension is strongly associated with vulnerability to ventricular fibrillation  
334 but not arrhythmia triggers following coronary occlusion in vivo. *Prog Biophysics Mol*  
335 *Biology* 2017;130:387–393. doi:10.1016/j.pbiomolbio.2017.05.012.
- 336 7. Barrabés JA, Garcia-Dorado D, Padilla F, Agulló L, Trobo L, Carballo J, et al. Ventricular  
337 fibrillation during acute coronary occlusion is related to the dilation of the ischemic region.  
338 *Basic Res Cardiol* 2002;97:445–451. doi:10.1007/s003950200051.

- 339 8. Rice JJ, Winslow RL, Dekanski J, McVeigh E. Model studies of the role of mechano-  
340 sensitive currents in the generation of cardiac arrhythmias. *J Theor Biol* 1998;190:295–312.  
341 doi:10.1006/jtbi.1997.0538.
- 342 9. Peyronnet R, Nerbonne JM, Kohl P. Cardiac mechano-gated ion channels and arrhythmias.  
343 *Circ Res* 2016;118:311–329. doi:10.1161/circresaha.115.305043.
- 344 10. Baumeister PA, Lawen T, Rafferty SA, Taeb B, Uzelac I, Fenton FH, et al. Mechanically-  
345 induced ventricular arrhythmias during acute regional ischemia. *J Mol Cell Cardiol*  
346 2018;124:87–88. doi:10.1016/j.yjmcc.2018.07.021.
- 347 11. Tang L, Joung B, Ogawa M, Chen P-S, Lin S-F. Intracellular calcium dynamics, shortened  
348 action potential duration, and late-phase 3 early afterdepolarization in Langendorff-perfused  
349 rabbit ventricles. *J Cardiovasc Electr* 2012;23:1364–1371. doi:10.1111/j.1540-  
350 8167.2012.02400.x.
- 351 12. Moparthy L, Zygmunt PM. Human TRPA1 is an inherently mechanosensitive bilayer-gated  
352 ion channel. *Cell Calcium* 2020;91:102255. doi:10.1016/j.ceca.2020.102255.
- 353 13. Bobkov YV, Corey EA, Ache BW. The pore properties of human nociceptor channel  
354 TRPA1 evaluated in single channel recordings. *Biochim Biophys Acta* 2010;1808:1120–  
355 1128. doi:10.1016/j.bbamem.2010.12.024.
- 356 14. Wang Z, Ye D, Ye J, Wang M, Liu J, Jiang H, et al. The TRPA1 channel in the  
357 cardiovascular system: promising features and challenges. *Front Pharmacol* 2019;10:1253.  
358 doi:10.3389/fphar.2019.01253.
- 359 15. Cameron BA, Stoyek MR, Bak JJ, Quinn TA. TRPA1 channels are a source of calcium-  
360 driven cardiac mechano-arrhythmogenicity n.d. doi:10.1101/2020.10.01.321638.



- 361 16. Brierley SM, Castro J, Harrington AM, Hughes PA, Page AJ, Rychkov GY, et al. TRPA1  
362 contributes to specific mechanically activated currents and sensory neuron mechanical  
363 hypersensitivity. *J Physiology* 2011;589:3575–3593. doi:10.1113/jphysiol.2011.206789.
- 364 17. Conklin DJ, Guo Y, Nystoriak MA, Jagatheesan G, Obal D, Kilfoil PJ, et al. TRPA1 channel  
365 contributes to myocardial ischemia-reperfusion injury. *Am J Physiol-Heart C*  
366 2019;316:H889–H899. doi:10.1152/ajpheart.00106.2018.
- 367 18. Zurborg S, Yurgionas B, Jira JA, Caspani O, Heppenstall PA. Direct activation of the ion  
368 channel TRPA1 by Ca<sup>2+</sup>. *Nat Neurosci* 2007;10:277–279. doi:10.1038/nn1843.
- 369 19. Andersson DA, Gentry C, Moss S, Bevan S. Transient receptor potential A1 is a sensory  
370 receptor for multiple products of oxidative stress. *J Neurosci* 2008;28:2485–2494.  
371 doi:10.1523/jneurosci.5369-07.2008.
- 372 20. Prosser BL, Ward CW, Lederer WJ. X-ROS Signaling: Rapid mechano-chemo transduction  
373 in heart. *Science* 2011;333:1440–1445. doi:10.1126/science.1202768.
- 374 21. Iribe G, Ward CW, Camelliti P, Bollensdorff C, Mason F, Burton RAB, et al. Axial stretch  
375 of rat single ventricular cardiomyocytes causes an acute and transient increase in Ca<sup>2+</sup> spark  
376 rate. *Circ Res* 2009;104:787–795. doi:10.1161/circresaha.108.193334.
- 377 22. Cameron BA, Kai H, Kaihara K, Iribe G, Quinn TA. Ischemia enhances the acute stretch-  
378 induced increase in calcium spark rate in ventricular myocytes. *Front Physiol* 2020;11:289.  
379 doi:10.3389/fphys.2020.00289.
- 380 23. Miura M, Wakayama Y, Endoh H, Nakano M, Sugai Y, Hirose M, et al. Spatial non-  
381 uniformity of excitation–contraction coupling can enhance arrhythmogenic-delayed  
382 afterdepolarizations in rat cardiac muscle. *Cardiovasc Res* 2008;80:55–61.  
383 doi:10.1093/cvr/cvn162.

- 384 24. Quinn TA, Granite S, Alessie MA, Antzelevitch C, Bollensdorff C, Bub G, et al. Minimum  
385 information about a cardiac electrophysiology experiment (MICEE): standardised reporting  
386 for model reproducibility, interoperability, and data sharing. *Prog Biophysics Mol Biology*  
387 2011;107:4–10. doi:10.1016/j.pbiomolbio.2011.07.001.
- 388 25. Khokhlova A, Iribe G, Yamaguchi Y, Naruse K, Solovyova O. Effects of simulated  
389 ischemia on the transmural differences in the Frank–Starling relationship in isolated mouse  
390 ventricular cardiomyocytes. *Prog Biophysics Mol Biology* 2017;130:323–332.  
391 doi:10.1016/j.pbiomolbio.2017.05.011.
- 392 26. Zheng Q, Jockusch S, Zhou Z, Blanchard SC. The contribution of reactive oxygen species to  
393 the photobleaching of organic fluorophores. *Photochem Photobiol* 2014;90:448–454.  
394 doi:10.1111/php.12204.
- 395 27. Baumeister P, Quinn TA. Altered calcium handling and ventricular arrhythmias in acute  
396 ischemia. *Clin Medicine Insights Cardiol* 2016;10s1:CMC.S39706.  
397 doi:10.4137/cmc.s39706.
- 398 28. Keurs HEDJ ter, Boyden PA. Calcium and arrhythmogenesis. *Physiol Rev* 2007;87:457–  
399 506. doi:10.1152/physrev.00011.2006
- 400 29. Michailova A, Lorentz W, McCulloch A. Modeling transmural heterogeneity of KATP  
401 current in rabbit ventricular myocytes. *Am J Physiol-Cell Ph* 2007;293:C542–C557.  
402 doi:10.1152/ajpcell.00148.2006.
- 403 30. Calaghan SC, White E. The role of calcium in the response of cardiac muscle to stretch.  
404 *Prog Biophysics Mol Biology* 1999;71:59–90. doi:10.1016/s0079-6107(98)00037-6.

- 405 31. Keurs HEDJ ter, Wakayama Y, Miura M, Shinozaki T, Stuyvers BD, Boyden PA, et al.  
406 Arrhythmogenic Ca<sup>2+</sup> release from cardiac myofilaments. *Prog Biophysics Mol Biology*  
407 2006;90:151–171. doi:10.1016/j.pbiomolbio.2005.07.002.
- 408 32. Wang YY, Chang RB, Waters HN, McKemy DD, Liman ER. The nociceptor ion channel  
409 TRPA1 is potentiated and inactivated by permeating calcium ions. *J Biological Chem*  
410 2008;283:32691–32703. doi:10.1074/jbc.m803568200.
- 411 33. Meents JE, Ciotu CI, Fischer MJM. TRPA1: a molecular view. *J Neurophysiol*  
412 2019;121:427–443. doi:10.1152/jn.00524.2018.
- 413 34. Meents JE, Fischer MJM, McNaughton PA. Agonist-induced sensitisation of the irritant  
414 receptor ion channel TRPA1. *J Physiology* 2016;594:6643–6660. doi:10.1113/jp272237.
- 415 35. Wang Z, Xu Y, Wang M, Ye J, Liu J, Jiang H, et al. TRPA1 inhibition ameliorates pressure  
416 overload-induced cardiac hypertrophy and fibrosis in mice. *Ebiomedicine* 2018;36:54–62.  
417 doi:10.1016/j.ebiom.2018.08.022.

418 **FIGURES**

419

420 **Figure 1 | Temporal uncoupling of voltage-Ca<sup>2+</sup> dynamics in ischemic ventricular myocytes**

421 **is reduced by block of K<sub>ATP</sub> channels with glibenclamide.** **a**, Schematic of the single-

422 excitation/dual-emission fluorescence imaging technique, utilising di-4-ANBDQPPQ (20 μM for

423 14 min) and Fluo-5F-AM (5 μM for 20 min) indicators and a single camera-image splitter system.

424 **b**, Trace of an action potential (AP, blue) and Ca<sup>2+</sup> transient (CaT, red) simultaneously recorded

425 in a contracting, paced (1 Hz) ventricular myocyte after 5 min exposure to either control (left), or

426 to SI solution alone (middle) or following pre-incubation with glibenclamide (20 μM for 15 min,


427 right). The calculated VP is shown in green.

428 **c**, Average APD<sub>50</sub> (blue) and CaTD<sub>80</sub> (red) after 5 min in either normal Tyrode (NT), or in SI alone or with glibenclamide (SI + GLIB).

429 **d**, Average VP in NT, SI, or SI + GLIB. Differences assessed by one-way ANOVA, with Tukey *post-hoc*


430 tests. \**p*<0.05 between groups. Error bars represent SEM.

431




432

433 **Figure 2 | Protocol for timed transient stretch of ventricular myocytes and arrhythmia**  
 434 **classification.** **a**, Rabbit ventricular myocyte before (top) and during (bottom) unidirectional axial  
 435 stretch using a carbon-fibre based system at increasing magnitudes of PZT displacement (left to  
 436 right: 20, 30, and 40  $\mu\text{m}$ ). **b**, Schematic of the protocol for cell stretch timed in mid-diastole and  
 437 the VP. **c**, Sarcomere trace of an ischemic cell (paced at 1 Hz, orange dots) that was stretched  
 438 (green) and maintained normal paced rhythm (NPR). **d**, Stretch-induced premature ventricular  
 439 contraction (PVC, blue segment). **e**, Stretch-induced delayed complex arrhythmia (red segment).  
 440 **f**, Stretch-induced sustained arrhythmic activity that spontaneously resolved. **g**, Stretch-induced  
 441 sustained arrhythmic activity that was terminated by rescue stretches.  
 442




443  
 444

445 **Figure 3 | Role of the VP in ischemic mechano-arrhythmogenicity.** Incidence of premature  
446 ventricular contractions (PVC, blue) and complex arrhythmias (red) with stretch during diastole  
447 or the VP after exposure to 5 min of normal Tyrode (NT), or to either SI alone or following pre-  
448 incubation with glibenclamide (20  $\mu$ M for 15 min, SI + GLIB). Differences in arrhythmic  
449 incidence assessed using chi-square contingency tables and Fisher's exact test. \* $p$ <0.05 between  
450 groups, \*\* $p$ <0.05 between diastolic and VP complexity within a group.  
451




452

453 **Figure 4 | Role of ROS and TRPA1 channels in ischemic mechano-arrhythmogenicity. a,**  
 454 Incidence of premature ventricular contractions (PVC, blue) and complex arrhythmias (red) with  
 455 stretch during diastole or the VP following pre-incubation with HC-030031 (10  $\mu$ M for 30 min)  
 456 and exposure to 5 min of SI. **b,** Incidence of arrhythmias with stretch during diastole or the VP in  
 457 ischemic cells incubated with voltage (di-4-ANBDQPQ, 20  $\mu$ M for 14 min) and Ca<sup>2+</sup> (Fluo-5F-  
 458 AM, 5  $\mu$ M for 20 min) indicators, without (middle) or with (right) photo-activation. **c,** Incidence  
 459 of arrhythmias during diastole or the VP in cells exposed to 5 min of SI pre-incubated with either  
 460 NAC (10 mM for 20 min), or DPI (3  $\mu$ M for 60 min). Differences in arrhythmic incidence assessed  
 461 using chi-square contingency tables and Fisher's exact test. \* $p$ <0.05 between groups.  
 462



463

464 **Figure 5 | Role of intracellular  $\text{Ca}^{2+}$  in ischemic mechano-arrhythmogenicity.** **a**, Incidence of  
465 premature ventricular contractions (PVC, blue) and complex arrhythmias (red) with transient  
466 stretch during diastole or the VP in cells exposed to 5 min of SI pre-incubated with BAPTA  
467 (middle; 1  $\mu\text{M}$  for 20 min), or with dantrolene (right; DNT, 1  $\mu\text{M}$  for 5 min). Differences in  
468 arrhythmic incidence assessed using chi-square contingency tables and Fisher's exact test.  $*p < 0.05$   
469 between groups,  $\#p < 0.05$  compared to NT group. **b**, Percent change in diastolic  $\text{Ca}^{2+}$  from control  
470 after 5 min exposure to SI, SI + NAC (10 mM for 20 min pre-incubation), or SI + HC-030031 (10  
471  $\mu\text{M}$  for 30 min pre-incubation). Differences assessed using unpaired Student's t-test between  
472 groups. Error bars represent SEM.  
473



474



475 **SUPPLEMENTAL METHODOLOGY**

476 **Ventricular myocyte isolation.** Single ventricular myocytes were enzymatically isolated from  
477 female New Zealand White rabbits ( $2.1 \pm 0.2$  kg, Charles River) euthanised by overdose through  
478 injection of pentobarbital (140 mg/kg) and heparin (1,500 units/kg, Sigma-Aldrich) into the  
479 marginal ear vein, followed by swift cardiac excision, aortic cannulation, and Langendorff  
480 perfusion (20 mL/min, 3-roller Watson-Marlow pump) with normal Tyrode (NT, 37 °C) solution  
481 (containing, in mM: 120 NaCl, 4.7 KCl, 1.0 MgCl<sub>2</sub>, 1.8 CaCl<sub>2</sub>, 10 glucose, 10 HEPES [Sigma-  
482 Aldrich], with pH adjusted to  $7.40 \pm 0.05$  with NaOH and an osmolality of  $300 \pm 5$  mOsm/L)  
483 bubbled with 100 % oxygen, for 10 min. The perfusate was then switched to a Ca<sup>2+</sup>-free solution  
484 (containing, in mM: 117 NaCl, 10 KCl, 1 MgCl<sub>2</sub>, 10 creatine, 20 taurine, 5 adenosine, 2 L-  
485 carnitine, 10 glucose, 10 HEPES [Sigma-Aldrich], with pH adjusted to  $7.40 \pm 0.05$  with NaOH  
486 and an osmolality of  $300 \pm 5$  mOsm/L) with the addition of 0.018 mM EGTA (Sigma-Aldrich),  
487 for 5 min. To begin enzymatic digestion, the perfusate was changed to the digestion solution (5  
488 min at 20 mL/min, Gilson minipuls 3 pump) comprised of Ca<sup>2+</sup>-free solution with the addition of  
489 200 U/mL Collagenase II (Worthington Biochemical Corporation), 0.06 mg/mL Protease XIV  
490 (from *Streptomyces griseus*, Sigma Aldrich), and 100 μM CaCl<sub>2</sub>, followed by a reduction in the  
491 perfusion rate to 15 mL/min until the heart became flaccid (~10-12 min). The left ventricular free  
492 wall was then removed and placed into 50 mL of stop solution, comprised of Ca<sup>2+</sup>-free solution  
493 with 0.5 % BSA (Sigma Aldrich) and 100 μM CaCl<sub>2</sub>. The ventricle was agitated and filtered  
494 through a 300 μm nylon mesh. The filtered tissue was resuspended in fresh stop solution, re-  
495 agitated, and re-filtered. The cell solution was split into 2 mL microcentrifuge tubes (VWR) and  
496 kept at room temperature (~22 °C, minimum 10 min). For experimentation, 1 mL of the

497 supernatant was replaced with NT and the cells were left to equilibrate (10 min). The supernatant  
498 was then replaced with 100 % NT.

499

500 **Carbon fibre technique.** Cells were subjected to unidirectional axial stretch using a pair of CFs  
501 (12-14  $\mu\text{m}$  in diameter) affixed to glass capillaries (1.12 mm inner / 2 mm outer diameter, World  
502 Precision Instruments) with cyanoacrylate adhesive and fastened in microelectrode holders  
503 (MEH820, World Precision Instruments) that were coupled to triaxial water hydraulic  
504 micromanipulators (MHW-103, Narishige) and mounted on linear PZT (P-621.1CD, Physik  
505 Instrumente). The left and right CF were trimmed to 1.2 mm (compliant, translating fibre) and 0.6  
506 mm (stiff, stationary fibre) in length, respectively.<sup>15,22</sup> CF position was controlled by a piezo  
507 amplifier / servo controller (E-665.CR, Physik Instrumente) driven by a voltage signal generated  
508 from a DAQ device (USB-6361; National Instruments) and dictated by custom LabVIEW routines  
509 (National Instruments). CF stiffness was calibrated with a force transducer system (406A, Aurora  
510 Scientific). Force was measured for a given PZT displacement and fitted by linear regression to  
511 the formula: stiffness = force / PZT displacement. CF bending was calculated by monitoring PZT  
512 and CF tip positions (recorded at 240 Hz, Myocyte Contractility Recording System, IonOptix) and  
513 applying the formula (CF bend = change in CF tip distance - change in distance between PZTs).  
514 Stretch force was assessed from these values (force = CF stiffness x CF bend).

515

516 **Cellular stretch.** A drop of the cell-containing solution was added to an imaging chamber (RC-  
517 27NE2, Warner Instruments) mounted on an inverted fluorescence microscope (IX-73, Olympus)  
518 with a 40 $\times$  objective (UPLFLN40X, Olympus). The chamber contained 1 mL of either NT or a  
519 simulated ischemic solution to mimic 30 min of acute ischemia (containing, in mM: 140 NaCl, 15

520 KCl, 1.8 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 1 NaCN, and 20 2-deoxyglucose to block oxidative  
521 phosphorylation and anaerobic glycolysis; pH adjusted to 6.5 with NaOH), maintained at 35 °C  
522 by a temperature controller (TC-344C, Warner Instruments).<sup>22,25</sup> The coverslip on the bottom of  
523 the chamber was coated with 20 µL of poly-2-hydroxyethyl methacrylate (poly-HEMA, Sigma-  
524 Aldrich) to prevent cellular adhesion. Once the cells had settled, bipolar electrical field stimulation  
525 (1 Hz, SIU-102, Warner Instruments) was commenced and contracting cardiomyocytes that were  
526 rod-shaped and clearly striated with intact membranes were chosen at random. Following cellular  
527 selection, pacing was halted, and the CFs were positioned at the lateral ends of the long axis of a  
528 cell and gently lowered onto the cell membrane using the triaxial hydraulic micromanipulators.  
529 Electrostatic adhesion of the cell to the CFs was confirmed by raising the cell off of the coverslip.  
530 Once cell attachment was established, electrical stimulation was recommenced, and cells  
531 contracted against the CFs for ~1-2 min to improve adhesion. After 5 min in the stop bath,  
532 unidirectional transient stretch (~112-173 ms total duration) using the compliant fibre was applied  
533 at a specific delay post-electrical stimulation, such that it occurred in two distinct time points of  
534 the electrical cycle: in mid-diastole or during the VP (as determined in initial experiments by  
535 simultaneous voltage-Ca<sup>2+</sup> fluorescence-based imaging in each treatment, described below). This  
536 was repeated once for a total of four stretches, as follows: (i) mid-diastole (600 ms delay after an  
537 electrical stimulus in all treatments), followed by a 10 s pause, and (ii) during the VP (delay  
538 adjusted to 300, 150, or 210 ms in NT, SI, or SI with glibenclamide, respectively) in late  
539 repolarisation, followed by a 10 s pause. This protocol was repeated at increasing magnitudes of  
540 PZT displacement (20, 30, and 40 µm, with an average 10±1, 16±1, and 18±2% change in  
541 sarcomere length, respectively), with 30 s between each increase in magnitude, for a total of 12  
542 stretches (Fig. 2a, b).

543 **Assessment of mechano-arrhythmogenicity.** Contractile function (diastolic sarcomere length,  
544 rate and percentage of sarcomere shortening) and characteristics of stretch (percent change in  
545 sarcomere length, stretched sarcomere length, and applied force) were assessed by monitoring  
546 sarcomere length and PZT and CF tip positions (as described above). Arrhythmic activity with  
547 stretch was classified from sarcomere measurements into either (i) premature ventricular  
548 contractions (PVC, 1 or 2 unstimulated contractions), or (ii) complex activity (including delayed  
549 arrhythmic activity and sustained arrhythmic activity that either spontaneously resolved or was  
550 terminated by an additional stretch; Fig. 2). When an arrhythmia occurred, the next stretch was  
551 delayed by the appropriate amount (either 10 or 30 s). To control for cellular damage, any stretch  
552 that resulted in CF slippage, or a sustained arrhythmia that could not be terminated by a maximum  
553 of 2 stretches was excluded.

554

555 **Dual parametric voltage-Ca<sup>2+</sup> fluorescence imaging.** The Ca<sup>2+</sup>-sensitive dye Fluo-5F, AM (5  
556 μM, ThermoFisher Scientific) and Pluronic F-127 (0.02 %, dissolved in DMSO, Biotium) were  
557 added to a microcentrifuge tube containing cells in 50% NT (20 min). The supernatant was then  
558 replaced with fresh full Ca<sup>2+</sup> NT, and the voltage-sensitive dye di-4-ANBDQPPQ (20 μM,  
559 University of Connecticut Health Centre) dissolved in ethanol was added to the tube and incubated  
560 for 14 min. The supernatant was again replaced with fresh NT, probenecid (1 mM, Sigma-Aldrich)  
561 was added, and the cells were maintained in the dark at room temperature until use (maximum 1  
562 hour). When ready for imaging, the solution containing dye-loaded cells was gently agitated with  
563 a transfer pipette and a small drop was added to 1 mL of the relevant solution (NT or SI) in the  
564 imaging chamber. CFs were adhered (as described above) to allow for proper positioning of cells,  
565 and to reduce motion with cellular contraction in the direction perpendicular to the imaging plane,

566 allowing for imaging without the use of an excitation-contraction uncoupler. Fluorescence was  
567 excited by a mercury lamp (U-HGLGPS, Olympus) passed through a 466/40 nm bandpass filter  
568 (FF01-466/40, Semrock) and reflected onto the sample by a 495 nm dichroic mirror (FF495-Di03,  
569 Semrock). For simultaneous measurement of transmembrane voltage and intracellular  $\text{Ca}^{2+}$ , each  
570 fluorescent signal was projected onto one-half of a  $128 \times 128$ -pixel, 16-bit electron-multiplying  
571 charge-coupled device (EMCCD) camera sensor (iXon3, Andor Technology) using an emission  
572 image splitter (Optosplit II; Cairn Research) and recorded at 500 fps with 2 ms exposure and  
573 maximum electron-multiplying gain. The two signals were split with a 685 nm dichroic mirror  
574 (FF685-Di02, Semrock) and Fluo-5F emission was collected with a 525/50 nm bandpass filter  
575 (FF03-525/50, Semrock) and di-4-ANBDQPQ emission with a 700 nm long-pass filter (HQ700lp;  
576 Chroma Technology). A schematic of the imaging setup is provided in Fig. 1a.

577 Analysis of voltage- $\text{Ca}^{2+}$  signals was performed using custom Matlab routines (R2018a,  
578 MathWorks). Whole-cell fluorescence was averaged, a temporal filter (50 Hz low-pass  
579 Butterworth) was applied, and bleaching was eliminated by fitting diastolic fluorescence over time  
580 with a second-order polynomial function and subtracting the result. From these signals, time to 20,  
581 30, 50, or 80 % recovery of the action potential (action potential duration, APD) or the  $\text{Ca}^{2+}$   
582 transient ( $\text{Ca}^{2+}$  transient duration, CaTD) were averaged over 3 consecutive cardiac cycles  
583 (Supplemental Fig. 1). The VP was calculated as the difference between  $\text{CaTD}_{80}$  and  $\text{APD}_{50}$ , a  
584 period during which myocytes start to become re-excitable while cytosolic  $\text{Ca}^{2+}$  remains elevated,  
585 plus the difference between the timing of the action potential and  $\text{Ca}^{2+}$  transient upstrokes  
586 (excitation-contraction coupling time, ECC):  $\text{VP} = (\text{CaTD}_{80} - \text{APD}_{50}) + \text{ECC}$  (Fig. 1b, d).

587 For assessment of the mechanical phase around the VP during fluorescence imaging  
588 (Supplemental Fig. 5), cells loaded with the voltage and  $\text{Ca}^{2+}$  indicators were stretched twice

589 during photoexcitation (40  $\mu\text{m}$  PZT displacement) with a 10 s pause in-between: once in diastole,  
590 and once in the VP. APD, CaTD, and VP values in these cells were calculated as above, and cross-  
591 compared with the timing of stretch, release, both, or neither within the VP.

592

593 **Ratiometric  $\text{Ca}^{2+}$  fluorescence imaging.** Ratiometric  $\text{Ca}^{2+}$  levels were assessed using the  $\text{Ca}^{2+}$   
594 indicator Fura Red-AM (5  $\mu\text{M}$ ; AAT Bioquest). Cells loaded with the dye were incubated with  
595 Pluronic F-127 (0.02 %) and probenecid (1 mM, dissolved in DMSO) for 20 min. Excitation was  
596 induced using alternating pulses from two white light-emitting diodes (CFT-90-W; Luminus  
597 Devices) each with a bandpass filter (420/10 nm, FF01-420/10, Semrock; or 531/22 nm, FF02-  
598 531/22, Semrock) that were combined into the microscope excitation light path with a 455 nm  
599 dichroic mirror (AT455dc, Chroma Technology) and reflected onto the sample by a 562 nm  
600 dichroic mirror (T562lpxr, Chroma Technology). Fluorescence emission was measured through a  
601 632/60 nm bandpass filter (AT635/60m, Chroma Technology) with an EMCCD camera at a rate  
602 of 500 fps, with 2 ms exposure time and maximum electron-multiplying gain. Light pulses and  
603 camera frame acquisition were synchronised with a custom control box (supplied by Dr. Ilija  
604 Uzelac, Georgia Institute of Technology) so that alternating frames corresponded to the signal  
605 generated by the two excitation wavelengths.

606 Analysis of intracellular  $\text{Ca}^{2+}$  was performed using custom Matlab routines. Whole-cell  
607 fluorescence was averaged, and a temporal filter (50 Hz low-pass Butterworth) was applied. The  
608 two  $\text{Ca}^{2+}$  signals were separated, and the ratio was calculated. Any remaining baseline drift was  
609 eliminated by fitting the resulting diastolic fluorescence signal with a second-order polynomial  
610 function and subtracting the result. From the corrected signals, the minimum value for each cardiac  
611 cycle (representing the diastolic  $\text{Ca}^{2+}$  level) was averaged over 3 consecutive cardiac cycles. To

612 assess changes in intracellular  $\text{Ca}^{2+}$  following exposure to SI, cells were first imaged in NT to get  
613 a baseline value, followed by a change to SI solution by perfusion at 2.1 mL/min through an inline  
614 heater (SF-28, Warner Instruments) for 2 min. Perfusion was stopped, and cells were maintained  
615 in the ischemia solution for 5 min before the second measurements were recorded.

616

617 **Code availability.** All custom computer source code used in this study is available from the  
618 corresponding author upon reasonable request.

619


620 **Data availability.** The datasets generated during and/or analysed during the current study are  
621 available from the corresponding author upon reasonable request.

622

623 SUPPLEMENTAL FIGURES

624




625 **Supplemental Figure 1 | Effect of normal Tyrode or simulated ischemia alone or following**  
626 **pre-incubation with glibenclamide on cellular voltage-Ca<sup>2+</sup> dynamics. a,** Average APD (blue)  
627 and CaTD (red) at 20, 30, 50, and 80% repolarisation after 5 min in normal Tyrode (NT) measured  
628 using a fluorescence imaging technique with voltage (di-4-ANBDQPPQ, 20  $\mu$ M for 14 min) and  
629 Ca<sup>2+</sup> (Fluo-5F-AM, 5  $\mu$ M for 20 min) fluorescent indicators and a single camera-image splitter  
630 system. **b,** Average APD (blue) and CaTD (red) at 20, 30, 50, and 80 % repolarisation after 5 min  
631 in SI. **c,** Average APD (blue) and CaTD (red) at 20, 30, 50, and 80 % repolarisation after 5 min in  
632 SI following pre-incubation with glibenclamide (20  $\mu$ M for 15 min, SI + GLIB). Differences  
633 assessed by one-way ANOVA, with Tukey *post-hoc* tests. \* $p$ <0.05 between groups, # $p$ <0.05  
634 compared to NT group, \*\* $p$ <0.05 compared to SI group. Error bars represent standard error of the  
635 mean.  
636



637




638 **Supplemental Figure 2 | Effect of complex arrhythmias on contractile function. a**, Diastolic sarcomere length  
639 sarcomere length **b**, percentage sarcomere shortening, and **c**, maximal rate of sarcomere shortening  
640 before and after resolution of a complex arrhythmia in ventricular myocytes exposed to 5 min of  
641 SI. Differences assessed by paired Student's t-test.  
642



643


644 **Supplemental Figure 3 | Mechanical parameters of cell stretch in ischemic cells. a**, Percentage  
645 sarcomere stretch, **b**, maximal stretched sarcomere length **c**, maximal applied force during-, and  
646 **d**, diastolic sarcomere length following rapid, transient stretch of rabbit isolated ventricular  
647 myocytes exposed to 5 min of SI with increasing levels of PZT movement (20, 30, and 40  $\mu\text{m}$ ).  
648 Differences assessed by one-way ANOVA with Tukey *post-hoc* tests.  $*p < 0.05$  within groups.  
649 Error bars represent standard error of the mean.  
650




651

652 **Supplemental Figure 4 | Effect of stretch magnitude on the incidence of mechano-**  
653 **arrhythmogenicity. a,** Incidence of premature ventricular contractions (PVC, blue) and complex  
654 arrhythmias (red) with rapid, transient stretch during diastole (left) and the VP (right) with  
655 increasing levels of PZT movement (20, 30, and 40  $\mu\text{m}$ ) in rabbit isolated ventricular myocytes  
656 exposed to 5 min of normal Tyrode (NT). **b,** Incidence of arrhythmias in cells exposed to 5 min of  
657 SI. Differences assessed using chi-square contingency tables and Fisher's exact test. *m* = stretches.  
658

**a**




**b**



659

660 **Supplemental Figure 5 | Role of stretch and/or release during the VP in ischemic mechano-**  
661 **arrhythmogenicity. a**, Fraction stretch pulse segment (only stretch, only release, or both stretch  
662 and release) that occurred within (IN) or outside (OUT) the VP in ischemic cells, revealed by  
663 fluorescence imaging (di-4-ANBDQPQ, 20  $\mu$ M for 14 min; and Fluo-5F-AM, 5  $\mu$ M for 20 min)  
664 combined with timed stretch. **b**, Of the stretch pulse segments revealed to be within the VP, the  
665 fractions that were (i) stretch only, (ii) release only, or (iii) both. Associated arrhythmias shown in  
666 red. **d**, Fraction of resultant arrhythmias during the VP associated with (i) stretch only, (ii) release  
667 only, or (iii) stretch and release. *m* = stretches, *c* = complex arrhythmias.  
668



669